Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Femasys (FEMY – Research Report). The associated price target remains the same with $15.00.
Emily Bodnar’s rating is based on the positive momentum Femasys is experiencing as it enters 2025, despite the lower-than-expected revenues in 2024. The company has announced several strategic partnerships with U.S.-based clinics, expanding the reach of its FemaSeed product to numerous centers across the country. This expansion is anticipated to drive revenue growth in 2025 as these partnerships mature.
Additionally, Femasys has achieved early EMA approval for the FemBloc delivery system, with full approval expected by mid-2025. This regulatory progress, combined with strategic partnerships in Spain for FemBloc distribution, positions the company well for future revenue generation. These factors contribute to the optimistic outlook for Femasys, justifying the Buy rating assigned by Emily Bodnar.
In another report released on March 18, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.